• Halozyme Therapeutics director Matthew L. Posard sold 5,230 common shares on Oct. 1, 2026.
• Sales prices ranged from $107.168 to $110.04 per share.
• Directly owned stake fell to 53,609 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-26-000133), on October 02, 2026, and is solely responsible for the information contained therein.